REFRACTORY MULTIPLE MYELOMA

This early-stage trial is testing a new oral drug called selvigaltin (GB1211) when added to a standard three-drug combination for multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find the safest dose and understand the side effec…

This study aims to see if a new two-drug combination (teclistamab and pomalidomide) works better than the current standard three-drug treatment for multiple myeloma that has come back after initial therapy. It will involve about 162 adults whose cancer has relapsed after one or t…

This is an early-stage study testing the safety of a new type of treatment called FT836 CAR T-cell therapy, given alongside an existing drug called daratumumab. It is for adults with advanced multiple myeloma that has come back or stopped responding to at least three prior treatm…

This study is for adults with high-risk multiple myeloma, a blood cancer, that has either returned after initial treatment or stopped responding to it. It compares a new two-drug combination (daratumumab + teclistamab) against two standard three-drug combinations. The main goal i…

This early-stage trial is testing a new, targeted radiation treatment for patients with high-risk multiple myeloma. The treatment involves an antibody that seeks out cancer cells and delivers a radioactive substance directly to them. This is given before a donor stem cell transpl…

This early-phase study is testing whether adding a personalized cancer vaccine can make a powerful cell therapy (CAR-T) work better for people with multiple myeloma that has come back or stopped responding to other treatments. The vaccine is made from a patient's own immune cells…

This study is testing a combination of four medications for people with multiple myeloma that has returned or stopped responding to prior treatments. The main goal is to find a safe and effective dose for the drug combination. Researchers will enroll about 62 adults to see if thi…